Your browser doesn't support javascript.
loading
Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.
Galldiks, Norbert; Kaufmann, Timothy J; Vollmuth, Philipp; Lohmann, Philipp; Smits, Marion; Veronesi, Michael C; Langen, Karl-Josef; Rudà, Roberta; Albert, Nathalie L; Hattingen, Elke; Law, Ian; Hutterer, Markus; Soffietti, Riccardo; Vogelbaum, Michael A; Wen, Patrick Y; Weller, Michael; Tonn, Joerg-Christian.
Afiliação
  • Galldiks N; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kaufmann TJ; Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
  • Vollmuth P; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.
  • Lohmann P; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Smits M; Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
  • Veronesi MC; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
  • Langen KJ; Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
  • Rudà R; Department of Radiology and Nuclear Medicine and Brain Tumour Center, Erasmus MC, Rotterdam, The Netherlands.
  • Albert NL; Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Hattingen E; Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
  • Law I; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.
  • Hutterer M; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
  • Soffietti R; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.
  • Vogelbaum MA; Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians-University of Munich, Munich, Germany.
  • Wen PY; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Weller M; Goethe University, Department of Neuroradiology, University Hospital Frankfurt, Frankfurt, Germany.
  • Tonn JC; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Neuro Oncol ; 26(7): 1181-1194, 2024 Jul 05.
Article em En | MEDLINE | ID: mdl-38466087
ABSTRACT
Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Imageamento por Ressonância Magnética / Tomografia por Emissão de Pósitrons Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Imageamento por Ressonância Magnética / Tomografia por Emissão de Pósitrons Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article